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Abstract
Background: The selection of patients according to key genetic characteristics may help to tailor chemotherapy
and optimize the treatment in Castration-Resistant Prostate Cancer (CRPC) patients. Functional polymorphisms
within the cytochrome P450 1B1 (CYP1B1) gene have been associated with alterations in enzymatic expression and
activity and may change sensitivity to the widely used docetaxel regimen.
Methods: CYP1B1 genotyping was performed on blood samples of 60 CRPC patients treated with docetaxel, using
TaqMan probes-based assays. Association between CYP1B1-142C>G (leading to the 48ArgGly transition), 4326C>G
(432LeuVal), and 4390A>G (453AsnSer) polymorphisms and treatment response, progression-free-survival (PFS) and
overall-survival (OS) was estimated using Pearson c
2 test, Kaplan-Meier curves and Log-rank test.
Results: Patients carrying the CYP1B1-432ValVal genotype experienced a significantly lower response-rate (P =
0.014), shorter progression-free-survival (P = 0.032) and overall-survival (P < 0.001). Multivariate analyses and
correction for multiple comparisons confirmed its prognostic significance for OS. No significant associations were
found among other polymorphisms and both response and clinical outcome.
Conclusions: CYP1B1-4326C>G (432LeuVal) polymorphism emerged as possible predictive marker of response and
clinical outcome to docetaxel in CRPC patients and may represent a potential new tool for treatment optimization.
Larger prospective trials are warranted to validate these findings, which might be applied to the future practice of
CRPC treatment.
Background
Prostate cancer is the most common malignancy in men
and the second leading cause of cancer death among
males in the Western World [1]. Approximately 70 to
80% of patients with advanced prostate cancer respond
to medical or surgical castration [2]. When tumours
become refractory to androgen withdrawal therapy,
most systemic treatments offer modest benefit in terms
of overall-survival (OS) [3].
Two multicenter phase III randomized clinical trials,
TAX 327 and SWOG 9916, showed a survival advantage
in Castration-Resistant Prostate Cancer (CRPC) patients
treated with taxane-based chemotherapy [4,5]. In both
trials the rates of prostate-specific-antigen (PSA)
response and OS were significantly higher in the doce-
taxel groups compared to mitoxantrone and prednisone.
In particular, PSA responses were 45% and 50%, while
OS was 18.9 and 17.5 months in docetaxel-treated
patients, in the TAX 327 and in the SWOG 9916 trial,
respectively. On the basis of these findings, taxane-based
chemotherapy is now considered the standard first-line
therapy for CRPC patients.
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patients, high variability in the clinical response to doce-
taxel has been observed [6]. This variability can be par-
tially attributed to a poor understanding of inter-
individual differences in the pharmacokinetics and phar-
macodynamics of docetaxel. Due to the clinical rele-
vance of docetaxel, genetic markers with predictive
power to assess inter-patient differences in clinical
response are urgently needed.
There is evidence from preclinical and clinical studies
that the cellular response to docetaxel is linked to
expression and/or activity of cytochrome-P450 1B1
(CYP1B1). Although docetaxel is not directly metabo-
lized by CYP1B1 [7,8], CYP1B1 overexpression resulted
in a significant decrease in docetaxel sensitivity in trans-
fected hamster ovary cells [9]. CYP1B1 was also induced
by docetaxel treatment as a mechanism of resistance in
several breast cancer cell lines; the same effect was not
observed in breast tumours following treatment with
other drugs, nor was it observed for docetaxel applied to
cell lines derived from tumours without significant hor-
mone-related etiology [10]. Recent evidence suggests
that this is probably due to the action of 4-hydroxyestra-
diol, the major CYP1B1 metabolite. The 4-OHE2-
derived quinone has been shown to impair docetaxel
antitumour activity through both an interference with
the microtubule stabilization induced by docetaxel, and
by direct structural alteration of docetaxel [11].
CYP1B1 activity is regulated by several functional
non-synonymous single-nucleotide-polymorphisms
(SNPs). The 4326C>G SNP (rs1056836), leading to the
432LeuVal (432LV) amino-acid transition, is associated
with increased catalytic activity of CYP1B1 [12,13],
while the 142C>G SNP (rs10012), leading to 48ArgGly
(48RG) transition, resulted in increased CYP1B1 gene
expression [12,14], without alterations in catalytic prop-
erties unless in combination with other functional
alleles. Finally, the 4390A>G SNP (rs 1800440), leading
to 453AsnSer (453NS) transition, has been associated
with decrease in protein expression due to an increase
in CYP1B1 degradation [15].
Interestingly, the homozygous variant of the 4326C>G
SNP (CYP1B1*3-allele) has been associated with
enhanced synthesis of 4-OHE2, increasing the intracellu-
lar ratio with the minor CYP1B1 metabolite 2-OHE2
[8], and CRPC patients carrying two copies of
CYP1B1*3 had a significantly shorter OS after doce-
taxel-based therapies [11].
However, no data on response were reported, and
further studies are needed to clarify the role of CYP1B1
genotype and docetaxel activity in CRPC patients. For
this purpose we retrospectively evaluated the correlation
between the 142C>G, 4326C>G and 4390G>A SNPs and
clinical outcome in 60 docetaxel-treated CRPC patients.
Methods
Patient selection criteria
The present study was performed in CRPC patients
treated with docetaxel between January 2005 and March
2007 in the Division of Oncology of the S.Chiara-Uni-
versity-Hospital (Pisa, Italy). Patients of age > 18, perfor-
mance status 0-3 (ECOG scale) with histologically
confirmed diagnosis of prostate cancer, were eligible for
the study. Other eligibility criteria were hormone refrac-
tory disease, ANC-count ≥ 1.5 × 10
3/ml, platelet-count
>1 0
5/ml, Hb > 10g/dl and life-expectancy > 3 months,
while exclusion criteria included hypersensitivity to doc-
etaxel and inadequate cardiac/epatic/renal function. The
Ethics Committee of S.Chiara-University-Hospital
approved the protocol. Patients were required to sign an
informed consent before their enrolment.
Treatment
All patients received docetaxel given intravenously over
1-hour at a dose of 75 mg/m
2 on day-1 every 21 days or
docetaxel 30 mg/m
2 weekly for five of every six weeks
plus prednisone 10 mg os daily.
Evaluation criteria
The primary endpoint of this analysis was the correla-
tion of the candidate polymorphisms with antitumour
response as determined by the effect of treatment on
PSA concentration, whereas secondary endpoints
included correlation with progression-free-survival (PFS)
and overall survival (OS). Serum PSA and physical
examination were evaluated every three weeks while CT
imaging and bone scan were performed at baseline and
every three cycles. A response was defined as a reduc-
tion from baselines of at least 50% that was maintained
for at least three weeks, whereas PSA progression was
defined as an increase from the nadir of either at least
25% for men with no PSA response or at least 50% for
all others. Stable disease was defined as an increase
from the nadir less than 25% for men with no PSA
response or less than 50% for all others. PFS was
defined from the date of randomization to the date of
PSA progression as an increase ≥ 25% in PSA level from
baseline or ≥ 50% from the lowest value achieved; the
PSA increase should be at least 5 ng/ml confirmed by
three measurements at 3 week intervals. Other criteria
of progressive disease were the appearance of a new
lesion or a ≥ 25% increase using standard bidimensional
measurements, in accordance with WHO guidelines, of
previously measured disease.
DNA isolation
Genomic DNA was extracted from blood samples (5 ml)
drawn before drug administration, using the QIAmp-
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and integrity were checked by optical density at 260 nm,
while testing for contamination was performed by mea-
suring absorbance at 280 nm and calculating the 260/
280 ratio.
Polymorphisms analysis
CYP1B1 polymorphisms at 48ArgGly, 432LeuVal and
453AsnSer were studied with Taqman®-probes-based
assays using the ABIPRISM-7900HT instrument
equipped with the Sequence-Detection-System version
2.0 software (Applied Biosystems, Foster City, CA). For-
ward (F) and reverse (R) primers and probes (P) were
obtained from Assay-on-Design-SNPs products, using
the File-Builder software version 2.0 (Applied Biosys-
tems), i.e. for 142C>G: (F) 5’-GCT GCT GAG GCA
ACG GA-3’;( R )5 ’-CAG TGG CCA CGC AAA CG-3’;
(VIC-P) 5’- C A GC T CC G GT C CG C - 3 ’ (FAM-P); 5’-
AGC TCG GGT CCG C-3’ for 4326C>G: (F) 5’-CAG
CTC GAT TCT TGG ACA AGG A-3’;( R )5 ’-TGC
CCA CTG AAA AAA TCA TCA CTC T-3’; (VIC-P) 5’-
CCT CAT CAA CAA GGA C-3’; (FAM-P) 5’-CTC ATC
AGC AAG GAC-3’; and for 4390A>G: (F) 5’- TTT GTC
AAC CAG TGG TCT GTG AAT-3’;( R )5 ’-GGA TCA
AAG TTC TCC GGG TTA GG-3’;( V I C - P )5 ’-CAT
GAC CCA CTG AAG TG-3’;( F A M - P )5 ’-ATG ACC
CAG TGA AGT G-3’.
PCR reactions were performed using 20 ng of DNA
diluted in 11.875 μl DNAse/RNAse-free water, 12.5 μl
of TaqMan Universal-PCR-Master-Mix, with AmpliTaq-
Gold®, and 0.625 μl of the assay mix (F and R primers
and the specific probes), in a total volume of 25 μl.
After thermal cycling (40 cycles of denaturation at 95°C
for 15 seconds, followed by annealing and extension at
60° for 1-minute), the instrument determined the allelic
content of each sample by reading the generated fluor-
escence, as described [16].
Statistics
This study was aimed at evaluating the correlation of
selected CYP1B1 SNPs with response to docetaxel, while
the secondary endpoints included the correlation with
PFS, and OS.
Demographic and clinical information on response
were compared across genotype, using Pearson-c
2 test.
Analyses included information on genotypes, ECOG-
performance status (PS, 0 vs. > 0), age (≤ median vs. >
median), pre-treatment PSA (≤ median vs. > median),
visceral metastatic disease (yes vs. no), anaemia (eg, Hb
< 13.0 g/dl, yes vs. no), and schedule (3 week vs. weekly
administration). PFS was calculated from the start of
chemotherapy to the date of clinical and/or biochemical
and/or radiological evidence of progression or death,
whichever occurred first. OS was calculated from the
day of treatment start to the endpoint (death or last fol-
low-up). The Kaplan-Meier method was used to plot
PFS and OS and the Log-rank test to compare curves.
Known baseline prognostic variables were also included
in multivariate analyses, using Cox’sp r o p o r t i o n a l
hazards model to identify factors of independent signifi-
cance. A step-down procedure was used based on the
likelihood ratio test, and hazard ratios were calculated
to estimate the magnitude and the direction of the
effect.
Data were analyzed using SPSS/PC+17 software (SPSS
I n c . ,C h i c a g o ,I L ) .S t a t i s t ical significance was set at P <
0.05. However, in the univariate analyses for clinical out-
come according to the 3 studied polymorphisms, a Bon-
ferroni correction required a P < 0.05/3 = 0.016 for
statistical significance.
Results
Patient characteristics, treatment and clinical response
A total of 60 consecutive patients were enrolled in this
study. Clinical characteristics are listed in Table 1. All
patients had CRPC with metastatic evaluable disease.
Median pre-treatment PSA value was 53.5 ng/ml (range
5.55-6024.00). All patients received docetaxel as first-
line treatment, administered every 3 weeks in 80.0% of
the patients, while 20.0% of them received docetaxel
weekly. Median cycles administered in all patients were
6 (range, 1-10). No toxic death occurred. Since the inci-
dence of grade-3 neutropenia was low and grade-4 toxi-
city was rare (1 case), no dose reduction was required.
All patients were evaluable for PSA response. Six
p a t i e n t sh a dC R ,2 3P R ,1 3S Da n d1 8P D .M e d i a nP F S
was 7.1 months (95% CI, 5.6-8.5), while median OS was
20.4 months (95% CI, 16.6-24.2).
Table 1 Characteristics of CRPC patients
N (%)
All Patients 60
Age, median (range) 71 years (58-84)
<7 1 31 (51.7)
>7 1 29 (48.3)
ECOG PS
0 51 (85.0)
1-3 9 (15.0)
Schedule
Weekly 12 (20.0)
3 weeks 48 (80.0)
Visceral metastasis
yes 17 (28.3)
no 43 (71.7)
Anaemia
yes 27 (45.0)
no 33 (55.0)
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All the samples were evaluable for CYP1B1 SNPs. For
the 4326C>G CYP1B1, the frequencies of CC, GC and
GG genotypes were 20%, 42% and 38%, respectively.
The wild-type CYP1B1 4390AA had a frequency of 62%,
while the heterozygous 4390AG and homozygous
4390GG variants had a frequency of 30% and 8%,
respectively. Regarding CYP1B1 142CG, the CC variant
was found in 13% of cases, while the heterozygous CG
and the GG variants were observed in 35% and 52% of
cases, respectively.
All polymorphisms followed Hardy-Weinberg’s equili-
brium as calculated with the SNP- analyzer-software (P
= 0.42, 0.31 and 0.46 for 4326C>G, 4390G>A and
142C>G CYP1B1 SNP, respectively). Genotype frequen-
cies of 4326C>G allele were comparable (P > 0.05, c
2-
test) with those reported in a study in a Caucasian
population of prostate cancer patients [17], while the
frequencies of 142C>G and 4390A>G were similar to
those observed in control Caucasian populations [18,8].
Patients and genotype characteristics were well balanced
between the 2 schedules of treatment. No significant
correlations were detected between genotype and the
other patient’s characteristics.
Correlation between clinical characteristics and outcome
The overall response rate (CR+PR = RR) of the patients
was 48.3%. Age, ECOG-PS, docetaxel-schedule, pre-
treatment PSA and visceral metastasis were not asso-
ciated with response (P = 0.443, 0.914, 0.846, 0.605 and
0.325 respectively), whereas anaemia was significantly
associated with response (22 out of the 29 responding
patients (eg, 75.9%) have Hb ≥ 13.0 g/dl, P = 0.004).
None of the clinical characteristics was associated with
PFS, while the occurrence of visceral metastasis and
anaemia were associated with significantly shorter OS.
In particular, median OS was 15.8 (95%CI, 12.4-19.1)
months in patients with Hb < 13.0 g/dl vs. 28.3 (95%CI,
16.9-39.7) months in patients with Hb ≥ 13.0 g/dl (P =
0.006). Similarly, patients with visceral metastasis had a
median OS of 13.9 (95%CI, 10.8-16.9) months, while
patients without visceral metastasis had a median OS of
23.2 (95%CI, 16.4-30.0) months (P = 0.001).
Finally, responding patients had a significantly longer
OS (28.9 (95%CI, 27.5-30.3) vs. 15.4 (95%CI, 12.0-18.8)
months, P < 0.001) and PFS (8.4 (95%CI, 7.8-8.9) vs. 4.1
(95%CI, 2.1-6.1) months, P = 0.009) than patients with
SD or PD.
Correlation between genetic polymorphisms and
outcome
When grouping patients between those with response
(CR and PR) and without response (SD and PD), and
between those with genotype leading to increased
CYP1B1 activity or expression (4326GG or 142GG) and
with genotype leading to reduced CYP1B1 expression
(4390AG or 4390GG), no significant correlations with
response were observed for the CYP1B1 polymorphisms
at position 4390 and 142 (Table 2). On the contrary, a
significant correlation was demonstrated between
response to docetaxel and CYP1B1 4326C>G poly-
morphism: 62.2% of the patients carrying the CYP1B1
4326CC and 4326CG genotype experienced CR or PR,
whereas only 26.1% of the CYP1B1 4326GG patients
responded to therapy (P = 0.014).
Patients harbouring both the CYP1B1 4326GG and
412GG genotype (N = 9) also experienced a significant
lower rate of response (P = 0.039), with respect to
patients (N = 51) harbouring the other genotypes.
Indeed, 8 out of 9 (88.9%) patients with the CYP1B1
4326GG and G412GG genotype experienced PD or SD,
while 28 out of 51 (54.9%) patients harbouring the other
genotypes achieved CR or PR. Furthermore, the patients
carrying both the CYP1B1 4326GG and the 4390AG or
4390GG genotype (N = 13) experienced a significant
lower prevalence of response with respect to patients (N
= 47) harbouring the other genotypes (P = 0.003).
Indeed, 12 out of 13 patients with the CYP1B1 4326GG
and the 4390AG or 4390GG genotype experienced PD
or SD, whereas 28 out of the 47 patients carrying the
other genotyes achieved CR or PR. In contrast, no dif-
ferences were observed grouping patients with the
CYP1B1 4390AG or 4390GG and the 412GG genotype
However, the CYP1B1 4326GG genotype was asso-
ciated with shorter PFS and OS (Fig. 1A-B). In particu-
lar, the median OS of patients harbouring the G/G
variant was 15.8 months, while patients carrying the C/
G or the C/C genotype had a median OS of 28.3
months, respectively (Fig. 1A). In order to keep at mini-
mum the probability to find a statistically significant dif-
ference purely by chance, the usual nominal level (P =
Table 2 Response according to CYP1B1 polymorphisms
CR+PR (N = 29) SD+PD (N = 31)
Genotype N (%) N (%) P
CYP1B1 4326CG
CC + GC 23 (62.2) 14 (37.8) 0.014
GG 6 (26.1) 17 (73.9)
CYP1B1 4390GA
AA 21 (56.8) 16 (43.2) 0.164
AG+ GG 8 (34.8) 15 (65.2)
CYP1B1 412CG
CC + CG 14 (48.3) 15 (51.7) 0.993
GG 15 (48.4) 16 (51.6)
Abbreviations: CR complete response; PD, progressive disease; PR, partial
response; SD, stable disease. P was calculated with Pearson-c2 two-sided test
with continuity correction
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Page 4 of 90.05) has been lowered to 0.016 by Bonferroni adjust-
ment for multiple comparisons considering the 3 stu-
died SNPs. After this adjustment, no statistically
significant differences were detected for PFS (P = 0.032),
while the CYP1B1 4326GG genotype was still signifi-
cantly correlated to OS (P < 0.001). The median age of
the 23 patients harbouring the CYP1B1 4326GG was 69
years (range = 58-80). Nine (39%) of these patients had
visceral metastasis, while 19 (83%) had anaemia. No sig-
nificant correlations were observed between OS and PFS
in patients grouped according to the other studied poly-
morphisms (Table 3). However, both the grouped
CYP1B1 4326GG and 412GG patients and the grouped
CYP1B1 4326GG and 4390GA or 4390GG patients had
significantly shorter OS (P = 0.001 and 0.022, respec-
tively), while no correlations were observed with PFS.
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Figure 1 Kaplan-Meier curves of OS (A) and PFS (B) according to CYP1B1 4326C>G polymorphism in the CRPC patients treated with
docetaxel enrolled in the present study (N = 60).
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regression analysis entering known prognostic baseline
factors (i.e. pre-treatment PSA, anaemia, visceral metas-
tasis) and the polymorphisms significantly associated
with OS in the univariate model (i.e. CYP1B1 4326C>G
polymorphism). In this model, limited by the small sam-
ple size, we found that response and visceral metastasis
were always associated with OS, while pre-treatment
PSA and anaemia were not independent predictors of
OS (Table 4). However, the CYP1B1 4326GG genotype
resulted a significant predictor of OS (P = 0.003). In a
second multivariate we also evaluated the grouped
CYP1B1 4326GG and 412GG as well as the grouped
CYP1B1 4326GG and 4390AG or 4390GG genotypes,
and both these grouped genotypes showed a significant
association with OS (P = 0.029 and P = 0.010,
respectively).
Discussion
This study investigated selected CYP1B1 polymorphisms
as potential biomarkers of activity/resistance to doce-
taxel in CRPC, and provides evidence that the CYP1B1
4326C>G polymorphism may be associated with
significantly lower response rate and shorter PFS/OS
after docetaxel treatment.
Therapeutic options against prostate cancer have been
expanded considerably in the last decade by the intro-
duction of docetaxel for the treatment of CRPC patients
[4,5]. Docetaxel is a second-generation drug of taxane
family, with marked activity against in vitro and in vivo
models of prostate cancer, where it has been shown to
induce apoptosis, inhibit angiogenesis and modulate
expression of several signaling pathways [19]. The pre-
clinical promise translated in clinical practice and doce-
taxel is effective as monotherapy and combination
therapy across a variety of tumour types, including pros-
tate cancer. The activity of docetaxel against CRPC has
been confirmed in the present work by the percentage
of PSA response and median OS, which were 48.3% and
20.4 months, respectively.
The reasons for therapeutic success or failure are,
however, elusive and few studies have evaluated possible
genetic markers to select patients most likely to respond
to docetaxel.
A major mechanism of resistance to taxanes may be
represented by the mutation/overexpression of tubulin.
In particular, β-tubulin-class-I mutations were identified
in 33% of 49 tissues from non-small-cell lung cancer
(NSCLC) patients, none of whom had an objective
response to paclitaxel [20], but we still lack the valida-
tion of mutational analysis or gene expression quantifi-
cation of tubulin-isotypes as predictive tests to tailor
treatment with taxanes.
Other studies have evaluated polymorphisms of the
multidrug resistance (MDR1) gene, whose product P-
glycoprotein functions as an ATP-dependent exporter of
several drugs, including paclitaxel and docetaxel, from
cells. Subjects homozygous for C in position 3435
(3435C>T) had higher MDR1 mRNA expression in leu-
kocytes than subjects with the TT genotype [21]. This
SNP together with the 2677G>A polymorphism, has
been associated with better response in NSCLC patients
treated with docetaxel-cisplatin chemotherapy, but no
significant correlations were found with response in
ovarian cancer patients treated with paclitaxel [22,23].
In CRPC patients receiving docetaxel alone, indivi-
duals carrying a diplotype consisting of the 1236C-
2677G-3435C MDR1 linked alleles had significantly
improved overall survival, but no data were available on
response [24].
Assessing germline genetic polymorphisms as either
predictive or prognostic markers is very appealing, espe-
cially in the CRPC patients. In these patients primary
tumours, as well as bone metastasis, are not resected so
that the avaibility of tumour material can be proble-
matic. SNPs are inherited genetic variants harboured by
all the cells and their analysis can be easily performed in
Table 3 PFS and OS according to CYP1B1 polymorphisms
Median PFS Median OS
Genotype Mos 95% CI P Mos 95% CI P
CYP1B1 4326CG
CC + GC 8.3 7.7-8.8 0.032 28.3 17.3-39.2 < 0.001
GG 4.8 2.0-7.6 15.8 5.3-26.3
CYP1B1 4390AG
AA 7.5 6.1-8.9 0.295 19.8 15.6-24.0 0.945
AG+ GG 7.0 2.6-11.3 10.4 11.3-29.5
CYP1B1 412CG
CC + CG 7.1 5.3-8.8 0.656 18.9 15.8-22.0 0.584
GG 7.5 5.9-9.1 21.2 13.2-29.1
Abbreviations: Mos, months; NR, not reached OS, overall survival; PFS,
progression-free-survival. P values were calculated with log-rank test.
Note. The event-rate was 51.7%, and 6 patients were alive without
progression at the last follow-up (July 2008).
Table 4 Multivariate analysis of clinical and biological
parameters for OS
Covariates HR (95% CI) df P
Visceral metastasis yes 3.8 (1.4-10.0) 1 0.008
no 1 (Ref.)
Anaemia yes 1.0 (0.2-2.5) 1 0.935
no 1 (Ref.)
Pre-treatment PSA ≤ median 1 (Ref.) 1 0.242
> median 0.64 (0.3-1.4)
CYP1B1 G4326C 4326CG+4326CC 1 (Ref.) 1 0.003
4326GG 1.7-12.8
Abbreviations: Ref., Reference.
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ting than tumour expression arrays, which need biopsies
of patient’s tumours, laser-microdissection and sophisti-
cated infrastructure.
Therefore, in the present study we evaluated func-
tional polymorphisms of CYP1B1, which play an impor-
tant role in cancer risk and progression as well as in the
metabolism of cancers modulated by sex hormones. In
particular, estrogen exposure has been implicated in the
disease aetiology of prostate cancer, and CYP1B1 is up-
regulated in prostate cancer [25]. Previous studies
showed that CYP1B1 polymorphisms may be involved in
cancer risk, alone or in combination with other factors
[8]. In particular, the 4326GG allele was associated with
increased cancer incidence in a Caucasian population
[ 1 7 ] ,w h e r et h ep r e v a l e n c eo ft h i sg e n o t y p ei nC R P C
patients (34%) was comparable to that observed in the
present study (36%).
However, this study focused on the analysis of
CYP1B1 polymorphisms in order to establish their pos-
sible relationships with clinical outcome in CRPC
patients treated with docetaxel.
The primary end-point of this study was the correla-
tion with response and significant response differences
were observed according to CYP1B1 4326C>G poly-
morphism. Patients carrying the CYP1B1 4326CC or the
4326CG genotype experienced positive clinical response
in a significantly higher rate than CYP1B1 4326GG
patients.
Since previous studies reported a linkage-disequili-
brium between the CYP1B1 4326GG and the 412GG
polymorphisms [26], we also performed a statistical ana-
lysis in patients harbouring the CYP1B1 4326GG and
412GG genotype. These patients experienced a signifi-
cantly lower rate of response, with respect to patients
harbouring the other genotypes.
Of note, the patients carrying both the CYP1B1
4326GG and the 4390AG or 4390GG genotype also
experienced a significantly lower response rate with
respect to all the patients harbouring the other geno-
types. However, the patients carrying the CYP1B1
412GG and the 4390AG or the 4390GG genotype had
similar response rate with respect to patients harbouring
the other genotypes, suggesting that the 4326GG geno-
type might be the best pharmacogenetic marker of
lower prevalence of response to docetaxel in CRPC
patients.
Furthermore, the CYP1B1 4326GG genotype was asso-
ciated with significantly shorter PFS and OS, whereas no
correlations were observed between both the grouped
CYP1B1 4326GG and 412GG and the grouped CYP1B1
4326GG and 4390AG or 4390GG genotypes with PFS.
Given the small number (N = 60) of patients enrolled
in the study, in order to evaluate whether other
prognostic factors could potentially explain their short
survival, we performed corrections for multiple compari-
son and checked carefully several known baseline demo-
graphic, pathological and biochemical characteristics
that predicted PSA decline and survival in previous stu-
dies in CRPC [27-29]. The occurrence of visceral metas-
tasis and anaemia were associated with shorter OS,
w h i l ea g e ,E C O G - P S ,a n dt h ed o c e t a x e ls c h e d u l ew e r e
not associated with outcome. However, in the multivari-
ate analysis, including all the significant variables from
t h eu n i v a r i a t ea n a l y s i s ,t h eCYP1B1 C4326C genotype
remained an independent predictive parameter of death
risk.
The underlying molecular mechanisms for the associa-
tion between CYP1B1 4326GG genotype and the
observed clinical outcome to docetaxel are not entirely
clear. In view of previous studies demonstrating no cor-
relation between docetaxel pharmacokinetics and
CYP1B1 genotype [7], as well as in vitro studies indicat-
ing that docetaxel is not directly metabolized by
CYP1B1 [30], this association could most likely be
caused by indirect interactions. The CYP1B1-mediated
17β-estradiol metabolites, such as the catechol estro-
gens, quinonal and semiquinonal catechol estrogens,
and methoxyestrogens can bind to tubulin at colchicine
binding site [31,32], and can interfere with the microtu-
bule stabilizing effect of docetaxel. This hypothesis is
supported by a previous work by Sissung et al. [11],
showing that the 4-OHE2-derived estrogen quinone
completely abrogates the polymerization of tubuline.
CYPY1B1-mediated estrogen metabolites that bind
tubulin are more prevalent in the 4326GG genotype,
and CRPC patients with this genotype had a significantly
shorter OS. These results were further supported by a
case report of a man with residual disease after radical
prostatectomy, treated successfully with docetaxel. After
only two cycles of therapy, a complete remission was
obtained and then consolidated with additional cycles of
docetaxel and radiotherapy. Prospective genetic analysis
showed that this patient was heterozygous for the
4326CG (432LeuVal) polymorphism [33].
However in the study by Sissung et al. [11] no associa-
tion was observed between 4326GG genotype and time-
to-progression. In contrast, breast cancer patients carry-
ing at least one C allele experienced a significantly
shorter PFS following high-dose paclitaxel-based combi-
nation chemotherapy [34]. Similarly, in our study, signif-
icant correlations were observed between PFS and OS in
patients grouped according to the 4326C>G polymorph-
ism. However no reproducible significant associations
between genotype and outcome were found for CYP1B1
polymorphism in a recent study in ovarian cancer
patients treated with carboplatin and taxane regimens in
the Scottish Randomised Trial in Ovarian Cancer phase
Pastina et al. BMC Cancer 2010, 10:511
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Page 7 of 9III trial [23]. These controversial results suggest that
pharmacogenetic associations may not always be repro-
ducible when explored in small size series, without stan-
dardized unbiased methods, as well as in different
settings for tumour type, stage and treatment. Further
studies in larger homogeneous populations are war-
ranted in order to understand the utility of candidate
polymorphisms in the prediction of outcome in specific
clinical settings.
Given the high variant allele frequencies of these poly-
morphisms, the statistical power to detect associations
with these SNPs and response is greatly improved.
Furthermore, we used very conservative statistical meth-
ods and correction for multiple comparisons to evaluate
these relationships and reduce the chances of spurious
findings. However, as most previous studies in this can-
cer setting, the present research is limited by the small
sample and residual confounding could have resulted in
our findings. Larger prospective studies are needed to
validate these preliminary results, after adjustment for
known prognostic factors. Furthermore, our data can
only suggest a prognostic role for the CYP1B1-4326GG
polymorphism, while its predictive role in docetaxel
resistance should be evaluated in a prospective rando-
mized study including a non-docetaxel containing arm.
Conclusions
The data from the present investigational study provide
the first evidence that the CYP1B1-4236GG polymorph-
ism is linked to the clinical response to docetaxel, and
may represent a potential new tool for treatment opti-
mization. These results should prompt to perform mul-
ticenter prospective clinical trials, to validate CYP1B1
polymorphisms as possible biomarkers of docetaxel
activity in CRPC patients.
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